The role of β-arrestins and E-cadherin in the pathogenesis of growth hormone- and prolactin-secreting pituitary adenomas: A literature review

Growth hormone- and prolactin-secreting pituitary adenomas are characterized by high variability of clinical course and response to therapy. In recent years, molecular biomarkers associated with the growth pattern and hormonal secretion of pituitary adenomas have been actively studied for their possible use as prognostic factors determining patient management tactics. Some of the promising molecules are β-arrestins and E-cadherin. β-arrestins are multifunctional adapter proteins that modulate proliferation, migration of a number of tumor cells and their sensitivity to antiproliferative therapy. E-cadherin is a key transmembrane protein of cell adhesion, which in addition to its structural role, is also regulates proliferation, differentiation and protection of cells from apoptosis. This review presents the results of studies included in the PubMed database concerning the role of β-arrestins and E-cadherin in the pathophysiology of growth hormone- or prolactin-secreting pituitary adenomas, with an emphasis on the potential to identify these proteins as biomarkers for predicting the effectiveness of drug therapy with somatostatin analogues in acromegaly and dopamine receptor agonists in prolactinomas.

1. СПИСОК ЛИТЕРАТУРЫ

2. Daly AF, Beckers A. The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020 Sep;49(3):347-355. doi: 10.1016/j.ecl.2020.04.002.

3. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z.

4. Przhiyalkovskaya E.G., Mokrysheva N.G., Troshina E.A. et al. Guidelines on diagnostics and treatment of acromegaly (draft). Obesity and metabolism. 2024;21(2):215-249. (In Russ.) doi: 10.14341/omet13153.

5. Dedov I.I., Melnichenko G.A., Dzeranova L.K. et al. Clinical guidelines ‘Hyperprolactinemia’ (draft). Obesity and metabolism. 2023;20(2):170-188. (In Russ.) doi: 10.14341/omet13002

6. Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi:10.1210/jc.2010-1692.

7. Fleseriu M, Biller BMK, Freda PU et al. Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb;24(1):1-13. doi:10.1007/s11102-021-01148-7.

8. Asa SL, Mete O, Perry A et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33, 6–26 (2022). doi: 10.1007/s12022-022-09703-7

9. Song Q, Ji Q, Li Q. The role and mechanism of β-arrestins in cancer invasion and metastasis (Review). Int J Mol Med. 2018 Feb;41(2):631-9. doi:10.3892/ijmm.2017.3288.

10. Smith JS, Rajagopal S. The β-arrestins: multifunctional regulators of G protein-coupled receptors. J Biol Chem. 2016 Apr 22;291(17):8969-77. doi:10.1074/jbc.R115.713313.

11. Aamna B, Kumar DA, Sahu R et al. Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis. J Cell Physiol. 2022 Oct;237(10):3717-33. doi:10.1002/jcp.30849.

12. Mangili F, Giardino E, Treppiedi D et al. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. Neuroendocrinology. 2021;111(6):568-79. doi:10.1159/000509219.

13. Genesio DM, Di Muro G, Barbieri AM et al. β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells. Cancers (Basel). 2023 Jun 16;15(12):3218. doi:10.3390/cancers15123218.

14. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 Mar;63(1):182-217. doi: 10.1124/pr.110.002642. Epub 2011 Feb 8. PMID: 21303898

15. Spada A, Mantovani G, Lania AG et al. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. Neuroendocrinology. 2022;112(1):15-33. doi: 10.1159/000514862.

16. Treppiedi D, Mangili F, Giardino E et al. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. Neuroendocrinology. 2020;110(7-8):642-652. doi: 10.1159/000503791.

17. Gatto F, Feelders R, van der Pas R et al. β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology. 2013 Dec;154(12):4715-25. doi: 10.1210/en.2013-1672. Epub 2013 Oct 29. PMID: 24169548.

18. Gatto F, Biermasz NR, Feelders RA et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol. 2016 May;174(5):651-62. doi: 10.1530/EJE-15-0391.

19. Coelho MCA, Vasquez ML, Wildemberg LE et al. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly. J Cell Mol Med. 2018 Apr;22(4):2110-6. doi:10.1111/jcmm.13427.

20. Akdemir AS, Metin Armagan D, Polat Korkmaz O et al. Association between β-arrestin-2 and filamin-A gene variations with medical treatment response in acromegaly patients. Minerva Endocrinol (Torino). 2025 Mar;50(1):32-41. doi: 10.23736/S2724-6507.21.03611-3.

21. Zasadkevich YuM, Brilliant AA, Sazonov SV. Role of cadherins in health and in developing breast cancer. Russian Journal of Archive of Pathology. 2015;77(3):57‑64. (In Russ.) doi: 10.17116/patol201577357-64.

22. Niessen CM, Leckband D, Yap AS. Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol Rev. 2011 Apr;91(2):691-731. doi:10.1152/physrev.00004.2010.

23. Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene. 2018 Sep;37(35):4769-80. doi:10.1038/s41388-018-0304-2

24. Burandt E, Lübbersmeyer F, Gorbokon N et al. E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomark Res 9, 44 (2021). doi: 10.1186/s40364-021-00299-4.

25. Kikuchi M, Yatabe M, Kouki T et al. Changes in E- and N-cadherin expression in developing rat adenohypophysis. Anat Rec (Hoboken). 2007 May;290(5):486-90. doi: 10.1002/ar.20516. PMID: 17373711

26. Qian ZR, Li CC, Yamasaki H, Asa SL et al. Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol. 2002 Dec;15(12):1357-65. doi:10.1097/01.MP.0000039572.75188.1A.

27. Qian ZR, Asa SL, Siomi H et al. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol. 2007 Dec;20(12):1269-77. doi:10.1038/modpathol.3800965.

28. Chauvet N, Romanò N, Meunier AC et al. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas. J Neuroendocrinol. 2016 Feb;28(2):12352. doi:10.1111/jne.12352.

29. Mendes GA, Haag T, Trott G et al. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly. Braz J Med Biol Res. 2017 Dec 11;51(2): e6808. doi: 10.1590/1414-431X20176808.

30. Fougner SL, Lekva T, Borota OC et al. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010 May;95(5):2334-42. doi:10.1210/jc.2009-2197.

31. Venegas-Moreno E, Flores-Martinez A, Dios E et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019 Mar;23(5):3088-96. doi:10.1111/jcmm.13851.

32. Puig-Domingo M, Gil J, Sampedro-Nuñez M et al. Molecular profiling for acromegaly treatment: A validation study. Endocr. Relat. Cancer 2020, 27, 375–389. doi:10.1530/ERC-18-0565.

33. Soukup J, Hornychova H, Manethova M et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J Cell Mol Med. 2021 Mar;25(5):2484-2492. doi: 10.1111/jcmm.16173.

34. Gliga MC, Chinezu L, Pascanu IM. Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. Int J Mol Sci. 2024 Aug 8;25(16):8663. doi: 10.3390/ijms25168663.

35. Marques-Pamies M, Gil J, Sampedro-Nuñez M et al. Personalized Medicine in Acromegaly: The ACROFAST Study. J Clin Endocrinol Metab. 2024 Jan;110(1):30-40. doi:10.1210/clinem/dgae444.